American Century Companies Inc. Sells 11,767 Shares of Nuvalent, Inc. $NUVL

American Century Companies Inc. lowered its holdings in Nuvalent, Inc. (NASDAQ:NUVL) by 3.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 362,931 shares of the company’s stock after selling 11,767 shares during the period. American Century Companies Inc. owned approximately 0.50% of Nuvalent worth $31,386,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Aster Capital Management DIFC Ltd acquired a new stake in shares of Nuvalent in the third quarter valued at approximately $38,000. Eastern Bank acquired a new stake in Nuvalent during the third quarter worth approximately $52,000. Persistent Asset Partners Ltd acquired a new stake in Nuvalent during the second quarter worth approximately $88,000. PNC Financial Services Group Inc. increased its stake in Nuvalent by 38.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,632 shares of the company’s stock worth $125,000 after acquiring an additional 451 shares during the period. Finally, Compass Wealth Management LLC bought a new position in Nuvalent during the 3rd quarter worth $172,000. Institutional investors and hedge funds own 97.26% of the company’s stock.

Nuvalent Trading Down 0.7%

Shares of NASDAQ NUVL opened at $99.41 on Friday. The company has a market cap of $7.23 billion, a price-to-earnings ratio of -16.99 and a beta of 1.32. Nuvalent, Inc. has a 12 month low of $55.53 and a 12 month high of $113.01. The stock has a 50-day moving average price of $103.04 and a two-hundred day moving average price of $96.04.

Insider Buying and Selling at Nuvalent

In related news, CFO Alexandra Balcom sold 7,084 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $110.32, for a total value of $781,506.88. Following the completion of the transaction, the chief financial officer owned 54,650 shares of the company’s stock, valued at $6,028,988. This represents a 11.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Christopher Durant Turner sold 4,236 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $97.32, for a total transaction of $412,247.52. Following the completion of the sale, the insider owned 58,311 shares in the company, valued at $5,674,826.52. This represents a 6.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 76,463 shares of company stock worth $7,722,489 over the last 90 days. 10.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on NUVL. The Goldman Sachs Group upped their target price on Nuvalent from $120.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Truist Financial set a $140.00 price target on Nuvalent in a research report on Monday, November 24th. Wedbush reaffirmed an “outperform” rating and issued a $125.00 price target (up from $120.00) on shares of Nuvalent in a research note on Monday, November 17th. Stifel Nicolaus upped their price objective on shares of Nuvalent from $115.00 to $135.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a research note on Thursday, January 22nd. Fifteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Nuvalent currently has an average rating of “Moderate Buy” and an average target price of $138.67.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: HC Wainwright raised near‑term quarterly EPS forecasts (Q1–Q4 2026) and materially trimmed the FY2026 loss estimate (improved from a larger loss to a smaller loss), supporting a positive revision to the short‑term earnings trajectory; the firm keeps a “Buy” rating and a $155 price target. MarketBeat: NUVL analyst note
• Positive Sentiment: HC Wainwright raised its FY2028 and FY2030 earnings forecasts (projecting future profitability in those years), which supports a longer‑term upside narrative if pipeline and commercialization progress meet expectations. MarketBeat: NUVL analyst note
• Neutral Sentiment: Analyst roundup coverage (The Globe and Mail) mentions Nuvalent alongside other healthcare names — useful context but not a firm‑moving, single‑source development. Investors should watch for company‑specific catalysts (trial data, commercial updates) to drive bigger moves. Analysts Offer Insights
• Negative Sentiment: HC Wainwright cut FY2027 EPS expectations (more negative than prior), indicating the analyst sees a bump in near‑term drag before the later recovery — this lowers near‑term profitability visibility. MarketBeat: NUVL analyst note
• Negative Sentiment: A separate note reported by AmericanBankingNews says HC Wainwright decreased FY2029 EPS estimates — a downgrade to that year’s outlook that tempers the optimistic long‑range thesis and may weigh on sentiment among longer‑horizon investors. FY2029 EPS Estimates Decreased

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.